Welcome to our dedicated page for Celularity news (Ticker: CELUW), a resource for investors and traders seeking the latest updates and insights on Celularity stock.
Celularity Inc. (Nasdaq: CELU; warrants: CELUW) is frequently in the news as a regenerative and aging-related cellular medicine company focused on placenta-derived biomaterials and cell therapies. Its news flow covers developments across wound care, longevity-focused cell therapy, ophthalmic biologics, and corporate and capital markets activity. Readers following CELUW-related headlines can use this page to see how Celularity’s scientific, clinical, commercial, and financing updates intersect with the value of its listed warrants.
Company press releases highlight clinical milestones, such as publication of Phase 2 trial results for PDA-002, a placenta-derived mesenchymal stromal-like cell therapy evaluated in complex diabetic foot ulcers with peripheral artery disease. Other news items describe real-world evidence for Biovance human amniotic membrane allograft products in chronic wound healing, as well as the impact of Medicare coverage and payment policies on skin substitute products used in wound care.
Celularity also reports on strategic partnerships that extend its platform into new settings. Examples include a collaboration with Fountain Life to supply stem cell therapy products for use under a Florida statute governing stem cell therapies in orthopedics, wound care, and pain management, and an exclusive sublicense and manufacturing role for DefEYE, Inc. in ophthalmic biologics, including Biovance, Biovance 3L, Interfyl, and CentaFlex.
In addition, Celularity’s news includes financing transactions, balance sheet restructuring, and Nasdaq listing compliance updates, all of which can influence perceptions of risk and opportunity around CELU common stock and CELUW warrants. Investors and observers can use this news feed to monitor clinical data releases, reimbursement and regulatory developments, strategic alliances, and capital structure changes that the company discloses over time.
Celularity (Nasdaq: CELU) reiterated its strategic commercialization partnership with NEXGEL (Nasdaq: NXGL) to license established biomaterial products and three 510(k) pathway programs. Celularity will be the exclusive manufacturer at its FDA-compliant Florham Park, New Jersey facility.
The transaction is expected to close no later than April 15, 2026, subject to customary closing conditions, and aims to leverage renewed regulatory and reimbursement clarity for placental-derived biomaterials.
Celularity (NASDAQ: CELU) entered definitive agreements to grant an exclusive license for its commercial-stage placental-derived biomaterials and certain development-stage programs, with upfront and milestone payments totaling up to $35 million and potential future royalties.
Celularity will remain the exclusive manufacturer at its Florham Park FDA-compliant facility, creating ongoing manufacturing revenue, and will realign operations to focus on longevity-focused cellular therapeutics and capital efficiency.
Celularity (Nasdaq: CELU) received $12.2 million in net cash proceeds from selling approximately $126.3 million of New Jersey net operating losses and $1.9 million of unused New Jersey R&D tax credits on Feb 10, 2026.
The sale was completed through New Jersey’s Technology Business Tax Certificate Transfer Program administered by the NJEDA, providing non-dilutive, tax-free capital to strengthen liquidity and support commercial and GMP-level cell therapy programs.
Celularity (NASDAQ: CELU) commented on CMS’s December 24, 2025 withdrawal of skin substitute Local Coverage Determinations (LCDs) that had been due to take effect January 1, 2026.
CMS withdrew the LCDs while leaving in place a new Medicare payment rate of $127.28 per square centimeter for skin substitute applications effective January 1, 2026. The withdrawn LCDs would have kept Celularity’s Biovance and Biovance 3L eligible; CMS’s action removed Medicare coverage for 158 other skin substitute products. CEO Dr. Robert J. Hariri highlighted real-world evidence (including reduced steroid use in about half of treated patients) and cited Celularity’s scalable GMP/GTP manufacturing in Florham Park, NJ as compatible with the new reimbursement.
Celularity (Nasdaq: CELU) announced closing of financing transactions on Dec 22, 2025 that provided $10.0 million in gross proceeds with up to an additional $2.0 million available subject to closing conditions. The financing combines a $7.0 million senior secured term loan (first-priority lien on substantially all assets) and secured convertible notes with aggregate commitments up to $5.0 million, convertible at $1.66 per share. Celularity also issued five-year warrants for 3,707,657 Class A shares exercisable from June 19, 2026 at $2.00 per share. The company said proceeds will support operations, strategic initiatives and its longevity-focused platform.
Celularity (Nasdaq: CELU) entered binding term sheets for financing expected to provide up to $12.0 million in private capital to support priorities in longevity and preservation of human performance.
Under the term sheets, Celularity expects initial proceeds of $10.0 million, comprising a $7.0 million senior secured term loan with a first‑priority lien on substantially all assets and secured convertible notes of up to $5.0 million convertible at $1.66 per share. The company will also issue warrants equal to 33% of the as‑converted principal, exercisable after six months at $2.00 per share. Transactions are private placements and contingent on definitive agreements.
Celularity (Nasdaq: CELU) announced a strategic partnership with DefEYE, including an exclusive sublicense and pricing arrangement tied to Celularity’s in-kind investment in DefEYE’s $12MM Series Seed Preferred Equity round.
DefEYE, formed from Verséa Ophthalmics leadership, reported ~70% sales growth in 2024 and plans to use funding to launch decellularized ophthalmic biologics including Biovance, Biovance 3L, Interfyl and related R&D. Celularity will be DefEYE’s exclusive contract manufacturer for the ophthalmic portfolio and retains the right to name one of five board members.
Celularity (Nasdaq: CELU) announced peer-reviewed publication of its Phase 2 trial of PDA-002, a placenta-derived cell therapy for diabetic foot ulcers (DFU) with and without peripheral artery disease (PAD), in the International Wound Journal on October 14, 2025.
The multi-center, randomized, double-blind trial enrolled 159 patients across 35 US sites. Patients received two intramuscular doses (3×10^6, 10×10^6, or 30×10^6 cells) or placebo. In the PAD subgroup, the 3×10^6 dose achieved 38.5% complete wound closure versus 22.6% for placebo. PDA-002 showed faster, more sustained healing, fewer new gangrene and foot infections, and no serious treatment-related safety signals through two years.
Celularity (Nasdaq: CELU), a regenerative medicine company, has filed its Q1 and Q2 2025 Form 10-Q reports and regained compliance with Nasdaq Listing Rule 5250(c)(1). The company has made significant progress in addressing financial challenges, including the retirement of $32.0 million in senior secured debt plus $9.6 million in unpaid interest.
Under CEO Robert J. Hariri's leadership, Celularity has implemented strategic changes including an internal restructuring with dedicated operating subsidiaries for each business unit. The company faced working capital pressures in H1 2025 due to wound care product reimbursement uncertainty and delayed cash collections. Management now believes Celularity is positioned to access traditional working capital facilities to support wound care sales growth and advance its three late-stage 510(k) pipeline products.
Celularity (NASDAQ:CELU), a regenerative and cellular medicine company, announced receiving a notice from Nasdaq on August 21, 2025, regarding its failure to file the Q2 2025 Form 10-Q. This marks the company's second delayed quarterly filing, following the Q1 2025 Form 10-Q.
The company is currently non-compliant with Nasdaq Listing Rule 5250(c)(1), though this notice does not immediately affect CELU's listing status. Nasdaq has given Celularity until September 5, 2025 to update its compliance plan, with a final deadline of November 17, 2025 to file all delinquent reports.